CD3 Overview
Molecule Name
T cell surface glycoprotein CD3
Synonyms
CD3
Drug Development Progress
Drugs in Clinical Trials198
Approved Drugs10
Highest Development StageApproved
Target Synonym
CD3 Complex
Background
CD3e molecule, epsilon is also known as CD3E, is a T-cell surface single-pass type I membrane glycoprotein. CD3E contains 1 Ig-like (immunoglobulin-like) domain and 1 ITAM domain. CD3E, together with CD3-gamma, CD3-delta and CD3-zeta, and the T-cell receptor alpha/beta and gamma/delta heterodimers, forms the T cell receptor-CD3 complex. This complex plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. The genes encoding the epsilon, gamma and delta polypeptides are located in the same cluster on chromosome 11. The epsilon polypeptide plays an essential role in T-cell development. CD3E plays an essential role in T-cell development, and defects in CD3E gene cause severe immunodeficiency. CD3E gene has also been linked to a susceptibility to type I diabetes in women. CD3E has been shown to interact with TOP2B, CD3EAP and NCK2.
CD3 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Recombinant Anti-EpCAM and Anti-CD3Human-mouse Chimeric Bispecific Antibody for Injection (Wuhan Yzy Biopharma Co Ltd) | M-701 | Phase 3 Clinical | Wuhan Yzy Biopharma Co Ltd | Ascites; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Hydrothorax; Neoplasms; Ovarian Neoplasms; Pleural Effusion, Malignant; Solid tumours; Stomach Neoplasms | Details |
| Etentamig | TNB-383B; ABBV-383 | Phase 3 Clinical | TeneoOne Inc | Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Waldenstrom Macroglobulinemia | Details |
| Brenetafusp | IMC-F106C; PRAME HLA-A02 | Phase 3 Clinical | Immunocore Ltd | Melanoma; Solid tumours | Details |
| Xaluritamig | AMG-509 | Phase 3 Clinical | Amgen Inc, Xencor Inc | Castration-Sensitive Prostate Neoplasms; Hormone-Sensitive Prostate Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Ewing | Details |
| QLS-32015 | QLS-32015; QLS32015 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Multiple Myeloma | Details |
| Obrixtamig | BI-764532; OBT620 | Phase 3 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Carcinoma, Neuroendocrine; Glioma; Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma | Details |
| Ramantamig | JNJ-79635322; JNJ-5322 | Phase 3 Clinical | Janssen Research & Development Llc | Multiple Myeloma | Details |
| Velinotamig | GR-1803 | Phase 3 Clinical | Chongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | Autoimmune Diseases; Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| Gamgertamig | CM-336; OM336 | Phase 3 Clinical | Keymed Biosciences Co Ltd | Amyloidosis; Anemia, Hemolytic, Autoimmune; Cytopenia; Evans syndrome; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Myositis; Purpura, Thrombocytopenic, Idiopathic; Sjogren's Syndrome; Skin Diseases, Vesiculobullous | Details |
| Pasritamig | JNJ-8343; JNJ-78278343 | Phase 3 Clinical | Janssen Research & Development Llc, Zymeworks Inc | Hormone-Sensitive Prostate Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| TQB-2825 | TQB-2825 | Phase 3 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell | Details |
| QLS-31905 | QLS-31905 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Bile Duct Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Surovatamig | TNB-486; AZD-0486; AZD0486 | Phase 3 Clinical | Teneobio Inc | Arthritis, Rheumatoid; Large B Cell Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Alveltamig | ZG-006; ZG006 | Phase 3 Clinical | Gensun Biopharma Inc, Suzhou Zelgen Biopharmaceuticals Co Ltd | Carcinoma, Neuroendocrine; Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details |
| Anti-CD3/humanized 3F8 bispecific antibody-activated T lymphocytes (University of Virginia) | Phase 2 Clinical | University Of Virginia | Neuroblastoma | Details | |
| GNR-084 | GNR-084 | Phase 2 Clinical | Generium Pharmaceuticals, Iontas | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) | Phase 2 Clinical | Huazhong University Of Science And Technology, Medimmune, University Of Michigan, University Of Virginia Cancer Center | Breast Neoplasms | Details | |
| Vibecotamab | XmAb-14045 | Phase 2 Clinical | Xencor Inc | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| α/β CD3+/CD19+ cell depleted stem cell therapy (New York Medical College) | Phase 2 Clinical | New York Medical College | Anemia; Anemia, Aplastic; Anemia, Sickle Cell; Hodgkin Disease; Kostmann Syndrome; Leukemia; Lymphoma, Non-Hodgkin; Thalassemia; Thrombocytopenia | Details | |
| Gocatamig | HPN-328; MK-6070; DS-3280 | Phase 2 Clinical | Harpoon Therapeutics | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | Details |
| Cibisatamab | RG-7802; RO-6958688; CEA-CD3 TCB; CEA-TCB | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours | Details |
| CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh | Female Urogenital Diseases; Inflammation; Primary Immunodeficiency Diseases | Details | |
| MDX-2003 | MDX-2003 | Phase 2 Clinical | ModeX Therapeutics Inc | Autoimmune Diseases; Leukemia, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Waldenstrom Macroglobulinemia | Details |
| JS-203 | JS-203 | Phase 2 Clinical | Shanghai Junshi Biological Engineering Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| MBS-303 | MBS-303; MSC-303; MSB-303 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Glomerulonephritis; Lupus Nephritis; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Nephrotic Syndrome | Details |
| JY-016 | JY-016 | Phase 2 Clinical | Beijing Eastern Biotech Co Ltd, Beijing Jingyitaixiang Technology Development Co Ltd | Colorectal Neoplasms; Lung Neoplasms; Solid tumours | Details |
| HBM-7022 | HBM-7022; AZD-5863 | Phase 2 Clinical | Harbour Biomed | Carcinoma, Pancreatic Ductal; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| EMB-07 | EMB-07 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Adenocarcinoma of Lung; Colorectal Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Neoplasms | Details |
| GB-261 | CND261; CND-261; GB-261 | Phase 2 Clinical | Genor Biopharma Co Ltd | Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Scleroderma, Systemic | Details |
| HER2 FPBMC therapy (University Of Virginia) | HER2 FPBMC | Phase 2 Clinical | University Of Virginia | Breast Neoplasms; Prostatic Neoplasms | Details |
| Anti-CD3 × Anti-EGFR Bispecific-armed T Cells (EGFR BATs) therapy | Phase 2 Clinical | University Of Virginia | Glioblastoma; Pancreatic Neoplasms | Details | |
| REGN-7041 | REGN7041; REGN-7041 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Uveitis | Details |
| GPRC5D/CD3 BiTEs | GPRC5D/CD3 BiTEs | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Multiple Myeloma | Details |
| ZGGS-34 | ZGGS34; ZGGS-34 | Phase 2 Clinical | Suzhou Zelgen Biopharmaceuticals Co Ltd | Solid tumours | Details |
| HY-05350 | HY-0005; HY-05350 | Phase 2 Clinical | Sichuan Huiyu Seacross Pharma Technology Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| Vonsetamig | REGN-5459 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Lupus Nephritis; Multiple Myeloma; Renal Insufficiency, Chronic | Details |
| NVG-222 | NVG-222 | Phase 2 Clinical | NovalGen Ltd | Hematologic Neoplasms; Neoplasms | Details |
| VNX-101 | VNX-101 | Phase 2 Clinical | Vironexis Biotherapeutics Inc | Burkitt Lymphoma; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Primary mediastinal B cell lymphoma | Details |
| BCD-248 | BCD-248 | Phase 2 Clinical | BIOCAD JSC | Multiple Myeloma | Details |
| Anti-CD3 x Anti-EGFR Bispecific Antibody (EGFRBi) Armed Fresh Peripheral Blood Mononuclear Cells therapy(University Of Virginia) | Phase 2 Clinical | University Of Virginia | Pancreatic Neoplasms | Details | |
| CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells therapy(Institute Of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Lymphoma, B-Cell | Details | |
| SHR-7787 | SHR-7787; SHR7787 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Small Cell Lung Carcinoma; Solid tumours | Details |
| MDX-2001 | MDX2001; MDX-2001 | Phase 2 Clinical | ModeX Therapeutics Inc | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Thyroid Neoplasms; Uterine Cervical Neoplasms | Details |
| SCTB-35 | SCTB35; SCTB-35 | Phase 2 Clinical | SinoCelltech Ltd | Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoma, B-Cell | Details |
| IBI-3003 | IBI3003; IBI-3003 | Phase 2 Clinical | Multiple Myeloma | Details | |
| MBS-314 | MBS-314 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Multiple Myeloma | Details |
| IMC-R117C | IMC-R-117-C | Phase 2 Clinical | Immunocore Holdings PLC | Colorectal Neoplasms; Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
| TQB-2934 | TQB2934; TQB-2934 | Phase 2 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Amyloidosis; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Neoplasms, Plasma Cell | Details |
| Mipletamig | APVO-436; APVO436 | Phase 2 Clinical | Aptevo | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| Emfizatamab | GNC-038 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd, SystImmune | Arthritis, Rheumatoid; Central Nervous System Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours | Details |
| CMD-011 | CMD-011 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms | Details |
| YK-012 | YK012 | Phase 2 Clinical | Excyte Biopharma Ltd | Glomerulonephritis, Membranous; Kidney Diseases; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Nephrosis; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| GEN-1047 | GEN-1047 | Phase 2 Clinical | Genmab A/S | Endometrial Neoplasms | Details |
| Olsutamig | REGN-4336 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| CM-350 | CM-350 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Solid tumours | Details |
| LBL-034 | LBL-034 | Phase 2 Clinical | Nanjing Leadsbiolabs Co Ltd | Multiple Myeloma; Neoplasms | Details |
| LBL-033 | LBL-033 | Phase 2 Clinical | Nanjing Leadsbiolabs Co Ltd | Neoplasms | Details |
| F-182112 | F182112; F-182112 | Phase 2 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| ICP-B02 | CM-355; ICP-B02 | Phase 2 Clinical | Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd | Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
| SMET-12 | SMET-12 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Nebratamig | GNC-035 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Solid tumours | Details |
| Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) | Phase 2 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma | Details | |
| CN-201 | CN-201; MK-1045 | Phase 2 Clinical | Curon Biopharmaceutical Ltd | Arthritis, Rheumatoid; Leukemia, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| EX-103 | EX-103; EX103 | Phase 2 Clinical | Guangzhou Excelmab Inc | Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin | Details |
| Anti-CD3 monoclonal antibody (Jinan Tiankang Biological Products) | Phase 2 Clinical | Jinan Tiankang Biological Products Co Ltd | Anemia, Aplastic | Details | |
| Cevostamab | RG-6160; BFCR-4350A; RO-7187797 | Phase 2 Clinical | Genentech Inc | Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute) | Phase 2 Clinical | Barbara Ann Karmanos Cancer Institute, University Of Virginia | Pancreatic Neoplasms | Details | |
| Ubamatamab | REGN-4018 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms | Details |
| Anti-CD3-anti-HER2-activated T cells | Phase 2 Clinical | Transtarget | Bone metastases; Breast Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
| A-319 | A-319 | Phase 1 Clinical | Evive Biotech Ltd | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Arthritis, Rheumatoid; Leukemia, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Podentamig | HPN-217; BCMA TriTAC | Phase 1 Clinical | Abbvie Inc, Harpoon Therapeutics | Multiple Myeloma | Details |
| Membrane bound ligand T-SIGn virus | NG-348 | Phase 1 Clinical | Akamis Bio Ltd | Neoplasms | Details |
| Flotetuzumab | S-80880; MGD-006; RES-234 | Phase 1 Clinical | Macrogenics Inc | Blastic Plasmacytoid Dendritic Cell Neoplasm; Hematologic Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Hairy Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Neoplasms, Plasma Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| NG-641 | EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAP | Phase 1 Clinical | Akamis Bio Ltd | Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Squamous Cell Carcinoma of Head and Neck | Details |
| MGD-014 | MGD-014 | Phase 1 Clinical | Macrogenics Inc | HIV Infections | Details |
| JNJ-63898081 | JNJ-63898081; JNJ-8081 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Neoplasms | Details |
| K-193 | K-193 | Phase 1 Clinical | Beijing Lvzhu Biological Technology Co Ltd | Lymphoma, B-Cell | Details |
| Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Pancreatic Neoplasms | Details | |
| Runimotamab | RO-7227780; BTRC-4017A; RG-6194 | Phase 1 Clinical | Genentech Inc | Solid tumours | Details |
| Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center | Phase 1 Clinical | Roger Williams Medical Center | Prostatic Neoplasms | Details | |
| Besufetamig | ONO-4685 | Phase 1 Clinical | Merus Nv | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Plaque psoriasis | Details |
| M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | M-802 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd, Wuhan Yzy Biopharma Co Ltd | Breast Neoplasms; Ovarian Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Emirodatamab | AMG-427 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
| SAR-442257 | SAR-442257 | Phase 1 Clinical | Sanofi | Neoplasms | Details |
| CC-1 | CC-1 | Phase 1 Clinical | BiconY Therapeutics Gmbh | Prostatic Neoplasms | Details |
| Acapatamab | AMG-160 | Phase 1 Clinical | Amgen Inc | Carcinoma, Non-Small-Cell Lung; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| Alnuctamab | EM-901; BMS-986349; CC-93269 | Phase 1 Clinical | Engmab Ag | Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| Pavurutamab | AMG-701 | Phase 1 Clinical | Amgen Inc | Multiple Myeloma | Details |
| EX-101 (Excelmab) | Phase 1 Clinical | ExcelMab Inc | Breast Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| HPN-536 | HPN-536 | Phase 1 Clinical | Harpoon Therapeutics | Neoplasms | Details |
| CC-3 | CC-3 | Phase 1 Clinical | Eberhard Karls University Of Tubingen, Germany | Breast Neoplasms; Colorectal Neoplasms; Gastrointestinal Neoplasms; Penile Neoplasms; Sarcoma | Details |
| MGD-020 | MGD020 | Phase 1 Clinical | Macrogenics Inc | HIV Infections | Details |
| BC-004 | BC-004 | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd | Breast Neoplasms; Solid tumours | Details |
| EX-105 | EX-105; EX105 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | Details |
| BA-3182 | BA-3182 | Phase 1 Clinical | Bioatla | Adenocarcinoma; Solid tumours | Details |
| BA-1202 | BA-1202 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours | Details |
| CLN-978 | CLN-978; NexGem | Phase 1 Clinical | Adimab LLC | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Sjogren's Syndrome | Details |
| MGD-024 | MGD-024 | Phase 1 Clinical | Macrogenics Inc | Blastic Plasmacytoid Dendritic Cell Neoplasm; Hodgkin Disease; Leukemia, B-Cell; Leukemia, Hairy Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms | Details |
| Cabotamig | ARB-202 | Phase 1 Clinical | Arbele Corp | Biliary Tract Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastrointestinal Neoplasms; Liver Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| CLN-049 | CLN-049 | Phase 1 Clinical | Eberhard-Karls Universitaet Tuebingen, German Cancer Research Center (Dkfz) | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| XmAb-819 | XmAb-819 | Phase 1 Clinical | Xencor Inc | Carcinoma, Renal Cell; Kidney Neoplasms | Details |
| NILK-2301 | NI-2301; NILK-2301 | Phase 1 Clinical | Novimmune Sa | Colorectal Neoplasms; Solid tumours | Details |
| SAR-446309 | AMX-818; HER2-XPAT; SAR-446309; VIR-5818 | Phase 1 Clinical | Amunix Pharmaceuticals Inc | Neoplasms; Solid tumours | Details |
| JNJ-95566692 | JNJ-95566692 | Phase 1 Clinical | Janssen Research & Development Llc | Lymphoma, Non-Hodgkin | Details |
| CD33Bi FPBMC (University Of Virginia) | Phase 1 Clinical | University Of Virginia | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases | Details | |
| VSV-02 | VSV-02 | Phase 1 Clinical | Joint Biosciences Ltd | Breast Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Solid tumours | Details |
| KT-501 | KT501; KT-501 | Phase 1 Clinical | Kali Therapeutics Inc | Arthritis, Rheumatoid | Details |
| INCA-035784 | INCA-035784; INCA035784 | Phase 1 Clinical | Incyte Corp | Myeloproliferative Disorders | Details |
| HLX-3901 | HLX-3901 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Carcinoma, Neuroendocrine; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours | Details |
| BiTE-EV Therapy(Beijing GoBroad Hospital) | Phase 1 Clinical | Beijing GoBroad Hospital | Leukemia | Details | |
| BGB-B455 | BGB-B455 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours | Details |
| SSS-59 | SSS59; SSS-59 | Phase 1 Clinical | Shenyang Sunshine Pharmaceutical Co Ltd | Neoplasms | Details |
| ABO-2203 | ABO2203; ABO-2203 | Phase 1 Clinical | Abogen Biosciences Co Ltd | Lymphoma, B-Cell | Details |
| LY-4152199 | LY-4152199; LY4152199 | Phase 1 Clinical | Eli Lilly And Company | Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| JNJ-70218902 | JNJ-70218902 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details |
| ARC-101 | ARC101; ARC-101 | Phase 1 Clinical | Third Arc Bio Inc | Endometrial Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Solid tumours | Details |
| DS-2243 | DS-2243a; DS-2243 | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Sarcoma; Solid tumours | Details |
| CLSP-1025 | CLSP-1025 | Phase 1 Clinical | Clasp Therapeutics Inc | Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms | Details |
| ZHB-015 | ZHB-015; ZHB015; ZHB-C003 | Phase 1 Clinical | Zonhon Biopharma Institute Inc | Solid tumours | Details |
| NPX-372 | NPX372; NPX-372 | Phase 1 Clinical | NextPoint Therapeutics Inc | Solid tumours | Details |
| APTN-101 | CBRX-101; APTN 101 | Phase 1 Clinical | Adaptin Bio Inc | Glioblastoma; Glioma | Details |
| TQB-2029 | TQB2029; TQB-2029 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Multiple Myeloma | Details |
| SAR-446368 | SAR446368; SAR-446368; VIR-5525; AMX-525 | Phase 1 Clinical | Amunix Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| GS-8588 | GS-8588 | Phase 1 Clinical | Gilead Sciences Inc | HIV Infections | Details |
| GNC-077 | GNC-077; GNC077 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Metastatic breast cancer; Solid tumours | Details |
| Mesothelin x CD3 Bispecific Antibody(Integral Molecular) | CT-95; LNK101; LNK-101 | Phase 1 Clinical | Integral Molecular Inc | Carcinoma, Ovarian Epithelial; Cholangiocarcinoma; Colorectal Neoplasms; Mesothelioma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| CM-380 | CM380; CM-380 | Phase 1 Clinical | Keymed Biosciences Co Ltd | Multiple Myeloma | Details |
| CMDE-005 | CMDE005; CMDE-005; CMD-E005 | Phase 1 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Solid tumours | Details |
| QL-335 | QL-335; QL335 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Colorectal Neoplasms | Details |
| LNF-2007 | LNF-2007; LNF2007 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Solid tumours | Details |
| QL-325 | QL-325 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd, Qlsf Biotherapeutics Inc | Leukemia, Myeloid, Acute | Details |
| JNJ-67571244 | JNJ-1244; JNJ-67571244; JNJ-67371244 | Phase 1 Clinical | Johnson & Johnson | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| QLS-4131 | QLS-4131; QLS4131 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| CTIM-76 | CTIM-76 | Phase 1 Clinical | Integral Molecular Inc | Endometrial Neoplasms; Neoplasms; Ovarian Neoplasms; Solid tumours; Testicular Neoplasms | Details |
| YKST-02 | YKST02; YKST-02 | Phase 1 Clinical | Excyte Biopharma Ltd | Multiple Myeloma | Details |
| JNJ-79032421 | JNJ-79032421; JNJ-2421 | Phase 1 Clinical | Janssen Research & Development Llc | Solid tumours | Details |
| JNJ-87890387 | JNJ-87890387 | Phase 1 Clinical | Janssen Research & Development Llc | Neoplasms; Solid tumours | Details |
| AMX-500 | VIR-5500; SAR-446329; SAR446329; AMX-500 | Phase 1 Clinical | Amunix Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| XmAb-541 | XmAb541; XmAb-541 | Phase 1 Clinical | Xencor Inc | Endometrial Neoplasms; Germinoma; Neoplasms, Germ Cell and Embryonal; Ovarian germ cell tumor; Ovarian Neoplasms | Details |
| [89Zr]Zr-BI-764532 | Phase 1 Clinical | Boehringer Ingelheim International Gmbh, C.H. Boehringer Sohn Ag & Co. Kg | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | Details | |
| TGI-6 | TGI-6 | Phase 1 Clinical | Hefei TG ImmunoPharma Co Ltd | Colorectal Neoplasms; Solid tumours | Details |
| SIM-0500 | SIM-0500; SIM0500 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| Recombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering) | Phase 1 Clinical | Hualan Genetic Engineering (Henan) Co Ltd | Multiple Myeloma | Details | |
| AMG 305 | AMG 305; AMG-305 | Phase 1 Clinical | Amgen Inc | Solid tumours | Details |
| Oncolytic Virus R130（Yunying Medical） | R130; R-130; R-130-OV | Phase 1 Clinical | Shanghai Yunying Medical Technology Co Ltd | Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Head and Neck Neoplasms; Kidney Neoplasms; Laryngeal Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Nose Neoplasms; Osteosarcoma; Otorhinolaryngologic Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Pharyngeal Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms | Details |
| SAIL-66 | SAIL66; SAIL-66 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours | Details |
| IMC-P115C | IMC-P-115-C; PRAME-HLE-A02 | Phase 1 Clinical | Immunocore Holdings PLC | Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Melanoma; Neoplasms; Ovarian Neoplasms; Sarcoma, Endometrial Stromal; Sarcoma, Synovial; Small Cell Lung Carcinoma; Solid tumours; Uterine Neoplasms | Details |
| RG-6524 | RO-7616789; ALPS-12; RG6524 | Phase 1 Clinical | F. Hoffmann-La Roche Ag | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | Details |
| BR-115 | CMG-6-A-19; CMG6A19; BR115; BR-115 | Phase 1 Clinical | Chengdu Chimagen Biosciences Co Ltd | Solid tumours | Details |
| OBT620 | OBT620 | Phase 1 Clinical | Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd | Small Cell Lung Carcinoma | Details |
| CBA-1535 | CBA-1535 | Phase 1 Clinical | Chiome Bioscience Inc | Carcinoma, Non-Small-Cell Lung; Mesothelioma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms | Details |
| JANX-008 | EGFR-TRACTr; JANX008; JANX-008 | Phase 1 Clinical | Janux Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| QLS-31903 | QLS31903; QLS-31903 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit) | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Hodgkin Disease; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous | Details | |
| QLF-32101 | QLF32101; QLF-32101 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| JANX-007 | PSMA-TRACTr; JANX-007 | Phase 1 Clinical | Janux Therapeutics Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| JNJ-80948543 | JNJ-80948543 | Phase 1 Clinical | Janssen Research & Development Llc | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasms | Details |
| PIT-565 | PIT-565 | Phase 1 Clinical | Novartis Pharma Ag | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Neoplasms; Nephrosis; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CC-312 | CC-312 | Phase 1 Clinical | CytoCares (Shanghai) Inc | Anemia, Hemolytic, Autoimmune; Arthritis, Rheumatoid; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Myositis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Purpura, Thrombocytopenic, Idiopathic; Scleroderma, Systemic | Details |
| ASP-2138 | ASP-2138 | Phase 1 Clinical | Astellas Pharma Global Development Inc, Xencor Inc | Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| ISB-2001 | ISB-2001; ABBV-2001 | Phase 1 Clinical | Ichnos Sciences Sa | Multiple Myeloma | Details |
| GR-1901 | GR1901; GR-1901 | Phase 1 Clinical | Chongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
| QLS-31904 | QLS-31904; QLS31904 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| RO-7428731 | RO-7428731; RG-6156 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Glioblastoma | Details |
| GBR-1342 | GBR-1342; ISB-1342 | Phase 1 Clinical | Glenmark Pharmaceuticals Ltd | Multiple Myeloma | Details |
| Recombinant humanized anti-CD19/CD3 bispecific antibody(New Time Pharmaceutical) | LNF-1904 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Leukemia, B-Cell; Lymphoma, B-Cell | Details |
| XmAb-968 | XmAb968 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Leukemia, Promyelocytic, Acute | Details |
| ONC-783 | ONC-783 | Phase 1 Clinical | Oncoc4 Inc | Neoplasms; Solid tumours | Details |
| 1-A-46 | 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110; BR-110; GSK-5926371 | Phase 1 Clinical | Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co Ltd | Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasms | Details |
| XmAb-18968 | XmAb-18968 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Leukemia, Myeloid, Acute | Details |
| SQZ-622(Novartis Pharma) | SQZ-622 | Phase 1 Clinical | Novartis Pharma Ag | Leukemia, Myeloid, Acute | Details |
| Forimtamig | RG-6234 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| RG-6232 | RG-6232 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Melanoma | Details |
| RG-6007 | RO-7283420; RG-6007 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Leukemia, Myeloid, Acute | Details |
| SAR-443216 | SAR-443216 | Phase 1 Clinical | Sanofi | Breast Neoplasms; Lung Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical) | BS-006; oHSV2-BiTEs; oHSV2CD3-PD-L1 | Phase 1 Clinical | Wuhan Binhui Biotechnology Co Ltd | Melanoma; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| JNJ-78306358 | JNJ-78306358; JNJ-6358 | Phase 1 Clinical | Janssen Research & Development Llc | Solid tumours | Details |
| TNB-585 | TNB-585; AMG-340 | Phase 1 Clinical | Teneobio Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| BC-3448 | BC-3448; BC3448 | Phase 1 Clinical | Wuxi BioCity | Solid tumours | Details |
| IBI-389 | IBI-389 | Phase 1 Clinical | Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| RGV-004 | RGV-004 | Phase 1 Clinical | Hangzhou Rongu Biotechnology Co Ltd | Lymphoma, B-Cell | Details |
| NVG-111 | NVG-111 | Phase 1 Clinical | NovalGen Ltd | Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Melanoma | Details |
| BI-765049 | BI-765049; OBT-624 | Phase 1 Clinical | Oxford Biotherapeutics Ltd | Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Cizutamig | EMB-06; CND-106; CN106 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Colitis, Ulcerative; Food Hypersensitivity; Graves Ophthalmopathy; Hypersensitivity, Immediate; Lupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis; Pemphigus; Scleroderma, Systemic | Details |
| GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Glioma; Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours | Details |
| RO-7425781 | RO-7425781 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| RO-7293583 | RO-7293583 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Melanoma; Skin Melanoma; Uveal melanoma | Details |
| Rezetamig | JNJ-8780; JNJ75348780; JNJ-75348780 | Phase 1 Clinical | Teneobio Inc | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | Y-150; Y150 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd, Wuhan Yzy Biopharma Co Ltd | Multiple Myeloma | Details |
| EX-101 | EX-101; EX101 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | Details |
| Plamotamab | XmAb-13676 | Phase 1 Clinical | Xencor Inc | Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Myositis | Details |
| A-337 | A-337 | Phase 1 Clinical | Evive Biotech Ltd | Neoplasms; Solid tumours | Details |
| CCW-702 | CCW-702 | Phase 1 Clinical | Abbvie Inc, The Scripps Research Institute Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| JCAR-014 | JCAR-014; JCAR021 | Phase 1 Clinical | Fred Hutchinson Cancer Research Center, Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute | Candidiasis; Hodgkin Disease; Leukemia; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary mediastinal B cell lymphoma | Details |
| PCART7-CD3 | PCART7-CD3 | Clinical | National University Of Singapore | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| InHeAb-01 | InHeAb-01; bsAB | Clinical | University Hospital Tuebingen | Neoplasms | Details |
| PMC2129G12 | PMC2129G12 | Forevertech Biotechnologies Co Ltd | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Mouse monoclonal antibody against human CD3 antigen of T lymphocyte (Wuhan Institute of Biological Products) | Approved | Wuhan Institute Of Biological Products Co Ltd | Mainland China | Rejection of organ transplantation | Wuhan Institute Of Biological Products Co Ltd | 1999-01-01 | Rejection of organ transplantation | Details | ||
| Tebentafusp | IMC-gp-100; ImmTAC-gp-100; IMC-gp100 | Approved | Immunocore Ltd | KIMMTRAK | United States | Uveal melanoma | Immunocore Ltd | 2022-01-25 | Melanoma; Skin Melanoma; Uveal melanoma | Details |
| Odronextamab | REGN-1979; ZL-1307 | Approved | Regeneron Pharmaceuticals Inc | ORDSPONO, Ordspono | EU | Lymphoma, Follicular | Regeneron Ireland Designated Activity Company | 2024-08-22 | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Plasmablastic Lymphoma | Details |
| Teclistamab | JNJ-64007957; JNJ-64007959; JNJ-7957 | Approved | Genmab A/S, Johnson & Johnson Innovative Medicine | TECAYLI, TECVAYLI, 泰立珂 | EU | Multiple Myeloma | Janssen-Cilag International Nv | 2022-08-23 | Hematologic Diseases; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Plasmablastic Lymphoma; Smoldering Multiple Myeloma | Details |
| Teplizumab | PRV-031; MGA-031; hOKT3-gamma-1-ala-ala; hOKT3-γ1-ala-ala | Approved | Tolerance Therapeutics Inc | TZIELD, Teizeild | United States | Diabetes Mellitus, Type 1 | Provention Bio Inc | 2022-11-17 | Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucose Intolerance; Hypoglycemia; Psoriasis; Rejection of renal transplantation | Details |
| Linvoseltamab | REGN-5458 | Approved | Regeneron Pharmaceuticals Inc | Lynozyfic | EU | Multiple Myeloma | Regeneron Ireland Designated Activity Company | 2025-04-23 | Food Hypersensitivity; Immunoglobulin Light-chain Amyloidosis; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Renal Insufficiency, Chronic; Smoldering Multiple Myeloma | Details |
| Mosunetuzumab | RG-7828; BTCT-4465A; RO-7030816; CD20-TBD | Approved | Genentech Inc | Lunsumio | EU | Lymphoma, Follicular | Roche Registration Gmbh | 2022-06-03 | Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Erythematosus, Systemic; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Richter's Syndrome | Details |
| Catumaxomab | LP000 | Approved | Neovii Biotech Gmbh, Trion Research | Removab, Korjuny | EU | Ascites | Lindis Biotech GmbH | 2009-04-20 | Ascites; Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Neoplasms; Ovarian Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| Epcoritamab | GEN-3013; ABBV-GMAB-3013 | Approved | Abbvie Inc, Genmab A/S | Tepkinly, TEPKINLY, EPKINLY | United States | Lymphoma, Large B-Cell, Diffuse | Genmab Us Inc | 2023-05-19 | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Primary mediastinal B cell lymphoma; Richter's Syndrome; Waldenstrom Macroglobulinemia | Details |
| Blinatumomab | BiTE-MT-103; bscCD19xCD3; AMG-103; MT-103; MEDI-538 | Approved | Micromet Inc | Blincyto, 倍利妥 | United States | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Amgen Inc | 2014-12-03 | Burkitt Lymphoma; Leukemia; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |